Aytu BioScience to Acquire Cerecor's Prescription Product Portfolio for $17M
Shots:
- Cerecor to receive up front as $4.5M in cash & $12.5M in Aytu preferred stock- which is approx. 1.4x LTM revenue- plus the assumption of debt
- The transaction will expand Aytu’s annual revenue to $44M and is expected to accelerate time to breakeven- following the acquisition of Innovus Pharmaceuticals
- The purchased commercial portfolio consists of six established- commercialized pediatric primary care products including AcipHex Sprinkle- Cefaclor for Oral Suspension- Karbinal ER- Flexichamber- Poly-Vi-Flor and Tri-Vi-Flor complimenting Aytu’s Natesto- ZolpiMist- and Tuzistra XR
Click here to read full press release/ article | Ref: Aytu BioScience | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com